DNA

GENENTECH INC

DNA

Overview Fund Activity

Delisted

DNA was delisted on the 26th of March, 2009.

Back to rankings

Healthcare Drug Manufacturers - General

Financial journalist opinion

Ginkgo Datapoints and Apheris Launch Antibody Developability Consortium

BOSTON--(BUSINESS WIRE)--Ginkgo Bioworks announced a series of new initiatives to accelerate the application of artificial intelligence in biologics drug discovery.

Ginkgo Datapoints and Apheris Launch Antibody Developability Consortium

Ginkgo Bioworks Issues Notice of Settlement of Shareholder Derivative Actions

BOSTON , Aug. 29, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today released the following notice: UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA OAKLAND DIVISION WEINING HU, derivatively on behalf of GINKGO BIOWORKS HOLDINGS, INC., a Delaware corporation, Plaintiff, vs.

Ginkgo Bioworks Issues Notice of Settlement of Shareholder Derivative Actions

Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Partner to Deploy AI-driven Lab-in-the-loop Workflows Across the Biopharma Industry

BOSTON , Aug. 20, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that its Datapoints offering has entered into a new strategic partnership with Inductive Bio and Tangible Scientific to make AI-driven lab-in-the-loop drug discovery broadly accessible across the industry. The partnership aims to deliver capabilities that previously required massive platform investments by combining high-throughput experimental workflows, streamlined compound management, and predictive chemistry AI models into a seamless integrated service that could help scientists design better drugs with fewer resources.

Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Partner to Deploy AI-driven Lab-in-the-loop Workflows Across the Biopharma Industry

Zacks Investment Research

Ginkgo Bioworks Holdings, Inc. (DNA) Recently Broke Out Above the 50-Day Moving Average

After reaching an important support level, Ginkgo Bioworks Holdings, Inc. (DNA) could be a good stock pick from a technical perspective. DNA surpassed resistance at the 50-day moving average, suggesting a short-term bullish trend.

Ginkgo Bioworks Holdings, Inc. (DNA) Recently Broke Out Above the 50-Day Moving Average

Ginkgo Automation Appoints Brian O'Sullivan as Head of Commercial to Accelerate External Growth

Seasoned life‑science executive to spearhead global go‑to‑market strategy as Ginkgo Automation scales external sales across biopharma, techbio, and new science‑driven markets while continuing to support internal programs. BOSTON , Aug. 12, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the appointment of Brian O'Sullivan as Head of Commercial for Ginkgo Automation.

Ginkgo Automation Appoints Brian O'Sullivan as Head of Commercial to Accelerate External Growth

Ginkgo Bioworks: Sell The Recent Rally

Ginkgo Bioworks' shares have rallied tremendously, and Q2 results showed a headline revenue beat with no upward guidance revision. Biosecurity segment guidance was cut, and overall revenue estimates have plunged, raising concerns about future growth. Despite cost reductions, Ginkgo continues to post large operating losses and faces ongoing cash burn, prompting a $500 million shelf offering.

Ginkgo Bioworks: Sell The Recent Rally

Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2025 Earnings Call Transcript

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q2 2025 Earnings Conference Call August 7, 2025 5:30 PM ET Company Participants Daniel Waid Marshall - Senior Manager of Communications and Ownership Jason Kelly - Founder, CEO & Director Steven P. Coen - Chief Accounting Officer & CFO Daniel Waid Marshall Good evening.

Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2025 Earnings Call Transcript

Ginkgo Bioworks Reports Second Quarter 2025 Financial Results

Ginkgo provides an update on its restructuring, including achievement of its expanded $250 million cost savings targets BOSTON , Aug. 7, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the second quarter ended June 30, 2025. The update, including a webcast slide presentation with additional details on the second quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com.

Ginkgo Bioworks Reports Second Quarter 2025 Financial Results

Ginkgo Bioworks Announces Date of Second Quarter 2025 Results Presentation

Presentation and Q&A session scheduled for post-market on Thursday, August 7, 2025 BOSTON , July 31, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com , and a replay will be made available.

Ginkgo Bioworks Announces Date of Second Quarter 2025 Results Presentation

Ginkgo to Deploy Modular Automation Technology to the Environmental Molecular Sciences Laboratory (EMSL) at Pacific Northwest National Labs (PNNL) to Accelerate Microbial Research for the Bioeconomy

Ginkgo will build a platform driven by its Reconfigurable Automation Carts (RACs) technology to enable EMSL's open-ended exploration of bioconomy-relevant microbes BOSTON , July 30, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that the Environmental Molecular Sciences Laboratory (EMSL) at Pacific Northwest National Laboratory (PNNL), a leading U.S. Department of Energy Office of Science user facility, has selected Ginkgo Automation to deliver a state-of-the-art automated anaerobic phenotyping platform at its Richland, Washington campus. This purchase marks a significant step in EMSL's mission to advance fundamental biological research supporting U.S. energy production, ensuring leadership in the bioeconomy, and establishing critical materials supply-chain resilience.

Ginkgo to Deploy Modular Automation Technology to the Environmental Molecular Sciences Laboratory (EMSL) at Pacific Northwest National Labs (PNNL) to Accelerate Microbial Research for the Bioeconomy

See News Rankings

Charts implemented using Lightweight Charts™